Every S-3 that Replimune Group, Inc. (REPL) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A S-3 covers the shelf registration that lets an established company sell over time, so if you follow REPL and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full REPL filings page.
Replimune Group, Inc. has filed an automatic shelf registration statement on Form S-3, allowing it to offer, from time to time after effectiveness, an unspecified amount of common stock, preferred stock, debt securities, warrants and units. Specific terms, prices and amounts for each takedown will be detailed in future prospectus supplements.
The company is a commercial-stage biotechnology business focused on oncolytic immunotherapy, including its product TUDRIQEV and additional candidates from its RPx platform. As of August 11, 2026, authorized capital consists of 150 million common and 10 million preferred shares, with 93,798,096 common shares issued and outstanding, alongside multiple series of pre-funded warrants.
Net proceeds from any future offerings are expected to be used for general corporate purposes, which may include working capital, capital expenditures, investments in subsidiaries, acquisitions and repurchases or redemptions of securities. The filing also describes extensive anti-takeover and governance provisions under Delaware law and the company’s charter, as well as standard debt, warrant and unit structures that may be used in future financings.
Replimune Group, Inc., a clinical-stage biotechnology company developing HSV-1–based oncolytic immunotherapies (including lead candidate RP1 with nivolumab in advanced melanoma), has filed an amended shelf registration to update a resale prospectus.
The filing covers the potential resale, from time to time, of 25,103,489 shares of common stock by entities affiliated with Baker Bros. Advisors. This consists of 11,045,336 currently held shares and 14,058,153 shares issuable upon exercise of Pre-Funded Warrants. Replimune will not receive proceeds from stockholder resales, only nominal proceeds if warrants are exercised.
The prospectus details RP1’s regulatory path, including Breakthrough Therapy designation, a BLA filed under the accelerated approval pathway, two FDA Complete Response Letters and a Class 1 BLA resubmission accepted with an August 2, 2026 action date and an advisory committee meeting set for July 30, 2026. Risk factors highlight substantial doubt about the company’s ability to continue as a going concern, with cash expected to fund operations only into the first calendar quarter of 2027 and significant dependence on the RP1 BLA outcome and future financing or strategic transactions.
Replimune Group, Inc. filed Amendment No. 1 to a shelf registration statement, covering the potential offering of up to $250,000,000 of common stock, preferred stock, debt securities, warrants, and units, to be sold from time to time. The filing also includes a sales agreement prospectus for an at-the-market program of up to $100,000,000 of common stock under a Sales Agreement with Leerink Partners LLC, which is included within the $250,000,000 aggregate. The amendment adds Rule 473(b) language for automatic effectiveness 20 days after filing.
The company states it may use net proceeds to fund continued development of its RPx platform, including indication expansion with RP1 in skin cancer and broadening RP2 development, and for general corporate purposes. Any unsold portion of the $100,000,000 ATM may be offered under the base shelf via prospectus supplement. Replimune’s common stock trades on Nasdaq as REPL; the last reported sale price was $8.58 on November 5, 2025.